Clinical Trials Sponsored by Zealand Pharma

Total 8954 results

Zealand Pharma

Recruiting

A Study to Inv. Safety,Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children<6 Years With T1D

Hypoglycemia

United States
Zealand Pharma

Recruiting

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS (EASE SBS 2)

Short Bowel Syndrome

United States, France, Belgium, Denmark, United Kingdom, Germany, Canada, Italy, Netherlands, Poland
Zealand Pharma

Active, not recruiting

A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Participants

Overweight | Healthy Volunteers | Obese

Germany
Zealand Pharma

Completed

A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Congenital Hyperinsulinism

United States, United Kingdom, Germany, Israel
Zealand Pharma

Completed

A First-in-human Study Looking at the Safety of ZP8396 and How it Works in the Body of Healthy Trial Participants

Overweight | Healthy Volunteers

Germany
Zealand Pharma

Completed

A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.

Healthy

Netherlands
Zealand Pharma

Completed

A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

Hypoglycemia | Diabetes Mellitus, Type 1

Canada, United States, Austria, Germany
Zealand Pharma

Completed

A Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

Healthy

Germany
Zealand Pharma

Completed

Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose

Inflammatory Bowel Disease

United States
Zealand Pharma

Enrolling by invitation

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial (EASE SBS 3)

Short Bowel Syndrome

Germany, United States, Belgium, Denmark, France, United Kingdom, Netherlands, Poland
Zealand Pharma

Completed

Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children

Hypoglycemia

United States, Germany, Slovenia
Zealand Pharma

Completed

Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM

Hypoglycemia | Diabetes Mellitus, Type 1

United States
Zealand Pharma

Completed

Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects

Healthy Subjects

United States
Zealand Pharma

Completed

Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed Glucagon

Hypoglycemia

Germany
Zealand Pharma

Completed

Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a Comparator

Hypoglycemia

Germany
Zealand Pharma

Active, not recruiting

Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism

Congenital Hyperinsulinism

United States, United Kingdom, Germany, Israel
Zealand Pharma

Completed

The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome (EASE SBS 4)

Short Bowel Syndrome

Denmark
Zealand Pharma

Completed

Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS) (EASE SBS 1)

Short Bowel Syndrome

United States, Denmark, Belgium, Germany, France, United Kingdom, Canada, Netherlands, Poland
Zealand Pharma

Completed

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Congenital Hyperinsulinism

United States, United Kingdom, Israel, Germany
Zealand Pharma

Completed

A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM

Hypoglycemia | Diabetes Mellitus, Type 1

Canada
Zealand Pharma

Withdrawn

Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults

Glucose Metabolism Disorders | Hypoglycemia
Zealand Pharma

Completed

A Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

Healthy

Germany
Zealand Pharma

Completed

Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration

Hypoglycemia

Germany
Zealand Pharma

Completed

Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function

Renal Impairment

Hungary, Poland
Zealand Pharma

Completed

Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction

Focus of Study is STEMI

Denmark
Zealand Pharma

Completed

ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon

Diabetes Mellitus Type 1

Germany
Zealand Pharma

Completed

Multiple Ascending Doses of ZP4207 Administered to HV to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207

Hypoglycemia

Germany
Zealand Pharma
SynteractHCR

Completed

A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus

Hypoglycemia | Diabetes Mellitus, Type 1

United States, Austria, Canada, Germany
Zealand Pharma
Syneos Health

Terminated

ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure

Heart Failure, Congestive

United States
Boehringer Ingelheim
Zealand Pharma

Completed

A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906

Liver Diseases | Healthy | Obesity

Germany, United States, Hungary, New Zealand, Slovakia, Poland
Hvidovre University Hospital
Zealand Pharma

Completed

Study of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide

Type 2 Diabetes Mellitus

Denmark
Zealand Pharma
Larix A/S

Completed

A Phase 2 Trial Testing ZP1848 in Patients With SBS (glepaglutide)

Short Bowel Syndrome

Denmark
University Hospital, Gentofte, Copenhagen
Zealand Pharma

Completed

GIP/GLP-1 Co-Activity in Subjects With Overweight and Type 2 Diabetes: Lowering of Food Intake (GASOLIN II)

Type 2 Diabetes Mellitus | Overweight and Obesity

Denmark
University Hospital, Gentofte, Copenhagen
Zealand Pharma

Active, not recruiting

Dapiglutide for the Treatment of Obesity (DREAM)

Inflammation | Obesity

Denmark
Zealand Pharma
Profil Institut für Stoffwechselforschung GmbH

Recruiting

A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

Safety and Tolerability

Germany
Zealand Pharma
Massachusetts General Hospital; Beta Bionics, Inc.

Completed

Feasibility Trial Testing the Bionic Pancreas With ZP4207 (dasiglucagon)

Diabetes Mellitus, Type 1

United States
Massachusetts General Hospital
Zealand Pharma; Beta Bionics, Inc.

Completed

The Bihormonal iLet Bionic Pancreas Feasibility Study

Type 1 Diabetes Mellitus

United States
Zealand University Hospital
University of Copenhagen; Pharma Nord; Psychiatric Research Unit, Region Zealand...

Completed

The Effect of MElatonin on Depression, Anxiety, CIrcadian and Sleep Disturbances in Patients After Acute Myocardial Syndrome (MEDACIS)

Depression | Acute Coronary Syndrome

Denmark
Zealand University Hospital
Region Zealand

Completed

Closure of Uterine Incision by Single or Double Layer Technique

Pregnancy

Denmark
Filip Krag Knop
Zealand Pharma

Active, not recruiting

Treatment of Post-bariatric Hypoglycaemia (SHERRY)

Hyperinsulinemic Hypoglycemia | Postprandial Hypoglycemia

Denmark
Region Zealand

Completed

Admission Pattern Among Children With Gastro-intestinal Infections Before and During the Covid-19 Pandemic

Gastroenteritis | Infectious Disease | Dehydration in Children | COVID-19 Pandemic | Norovirus Infections | Rota Virus Gastroenteritis

Denmark
Region Zealand

Unknown

Internal Hernias After Gastric Bypass Can be Prevented Safely With Primary Closure of All Mesenteric Defects With Clips

Internal Hernias

Denmark
Region Zealand

Recruiting

Botulinum Toxin for Chronic Neuropathic Pain

Chronic Pain | Neuralgia

Denmark
Region Zealand

Completed

Reconstruction of the Anterior Cruciate Ligament(ACL-R) in the 30+-Year Old Assessed by Patient Reported Outcome Measures(PRO) Using the Nationwide Danish Knee Ligament Reconstruction Registry

Cruciate Ligament Rupture

Denmark
Region Zealand

Completed

Subjective Outcomes After ACL Reconstruction With BQT Autograft

Knee Injuries | ACL Injury
Region Zealand

Completed

Changes in Preference for Surgery of Patients Signed up for Arthroscopic Procedures

Arthroscopy

Denmark
Zealand University Hospital
University of Copenhagen; Region Zealand

Unknown

Is Serum YKL-40 Capable of Predicting Intrauterine Growth Restriction (IUGR) and Preeclampsia?

Preeclampsia | Intrauterine Growth Restriction

Denmark
Zealand University Hospital

Not yet recruiting

MONitoring Sedentary Behavior and Light Physical Activity in Patients With Stroke (MONSS)

Stroke, Acute | Sedentary Behavior | Behavior | Physical Inactivity
Zealand University Hospital

Recruiting

ITP Block: Single or Multiple Injection?

Anesthesia, Local

Denmark
Zealand University Hospital

Recruiting

Nurse-led Sheath Insertion in Cardiac Patients (NUSHI)

Coronary Artery Disease

Denmark

3

Subscribe